Skip to main content
. 2022 Apr 5;12:5717. doi: 10.1038/s41598-022-09696-7

Table 1.

Demographic and clinical data of the patient population at baseline.

Gender (M/F) 10 M
Age (years) 57.0 ± 10.2
Dry body weight (kg) 74.7 [69.7;89.1]
Dialysis vintage (months) 23.1 [12.5;40.9]
Renal disease Autosomal dominant polycystic kidney disease (n = 3); IgA nephropathy (n = 2); diabetic nephropathy (n = 1); reflux nephropathy (n = 1); focal segmental glomerulosclerosis (n = 1); membranous glomerulonephritis (n = 1); Alport (n = 1)
Regular anticoagulation dose Enoxaparin 40 mg (n = 5); Tinzaparin 3500 (n = 4); Enoxaparin 60 mg (n = 1)
Platelet inhibitors Acetylsalicylic acid 80 mg (n = 7)
Hb (g/dL) 12.0 ± 0.7
Platelets count (103/µL) 224 ± 56
aPTT (s) 34.6  ± 2.6
INR (-) 1.0  ± 0.1
CRP (mg/L) 5.2 [2.3;7.0]

Hb: hemoglobin; aPTT: activated partial thromboplastin time; INR: international normalized ratio; CRP: C-reactive protein.